Generex Biotechnology Presents Clinical Trial Results at Scientific Symposia

Oct 04, 2005, 01:00 ET from Generex Biotechnology Corporation

    TORONTO, Oct. 4 /PRNewswire-FirstCall/ -- Generex Biotechnology
 Corporation (Nasdaq:   GNBT), a leader in the area of buccal drug delivery,
 today announced that Dr. Jaime Guevara-Aguirre, of the Institute of
 Endocrinology IEMYR in Quito, Ecuador and one of the principal investigators
 in the Company's on-going clinical trials of Oral-lyn(TM), its proprietary
 oral insulin spray product, made a presentation of Oral-lyn(TM) clinical
 trials results at the 7th Hong Kong Diabetes and Cardiovascular Risk Factors -
 East Meets West Symposium on October 2, 2005.  Dr. Guevara-Aguirre made an
 oral presentation of an abstract entitled "Addition of Oral-lyn(TM) at
 Mealtimes in Subjects with Type-2 Diabetes Maintained on Glargine + Metformin
 - A Comparison with Placebo".  The abstract was coauthored by Professor Itamar
 Raz of Hadassah Hospital, Jerusalem, Israel (another Oral-lyn(TM) principal
 investigator) together with M. Kidron (also of Hadassah Hospital) and M.
 Dubinsky and J. Wainstein of Wolfson Hospital, Holon, Israel.
     In addition, Dr. Gerald Bernstein, the Company's Vice-President for
 Medical Affairs, will be making the following poster presentations at the Drug
 Discovery to Drug Development Global Partnering and New Science symposium in
 Mumbai, India from October 5 - 7, 2005:
 
     -- "A Series of Open-label Studies Comparing Various Formulations of
         Orally Administered Insulin (Oral-lyn(TM)) in Patients with Type-1
         Diabetes Mellitus (DM)", a study  coauthored by Dr. Jaime Guevara-
         Aguirre, Marco Guevara and Jeannette Saavedra of the Institute of
         Endocrinology IEMYR in Quito, Ecuador;
 
     -- "A 12-Day Comparison of Preprandial Humulin(R) vs. Oral-lyn(TM) in 10
         Type 1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy",
         a study coauthored by Dr. Jaime Guevara-Aguirre, Marco Guevara and
         Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito,
         Ecuador; and
 
     -- "Addition of Oral-lyn(TM) at Mealtimes in Subjects with Type 2 Diabetes
         Maintained on Glargine + Metformin - A Comparison with Placebo," a
         study coauthored by Professor Itamar Raz of Hadassah Hospital,
         Jerusalem, Israel together with M. Kidron (also of Hadassah Hospital)
         and M. Dubinsky and J. Wainstein of Wolfson Hospital, Holon, Israel.
 
     "The continuing acceptance at these significant scientific symposia of
 Oral-lyn(TM) studies is indicative of the increasing recognition in the global
 scientific community of our product's potential for providing a vast
 improvement in the quality of life of patients with diabetes," said Anna
 Gluskin, the Company's President & Chief Executive Officer.  "In addition, we
 welcome the increased exposure of Oral-lyn(TM) in the scientific communities
 in China and India, two potentially enormous markets for the product."
 
     About Generex
     Generex is engaged in the research and development of drug delivery
 systems and technologies.  Generex has developed a proprietary platform
 technology for the delivery of drugs into the human body through the oral
 cavity (with no deposit in the lungs).  The Company's proprietary liquid
 formulations allow drugs typically administered by injection to be absorbed
 into the body by the lining of the inner mouth using the Company's proprietary
 RapidMist(TM) device.  The Company's flagship product, oral insulin
 (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the
 treatment of patients with Type-1 and Type-2 diabetes, is in various stages of
 clinical trials around the world.
 
     For more information, visit the Generex Web site at
 http://www.generex.com.
 
     Safe Harbor Statement: This release and oral statements made from time to
 time by Generex representatives concerning the same subject matter may contain
 "forward-looking statements" within the meaning of the Private Securities
 Litigation Reform Act of 1995.  These statements can be identified by
 introductory words such as "expects," "plans," "intends," "believes," "will,"
 "estimates," "forecasts," "projects" or words of similar meaning, and by the
 fact that they do not relate strictly to historical or current facts.
 Forward-looking statements frequently are used in discussing potential product
 applications, potential collaborations, product development activities,
 clinical studies, regulatory submissions and approvals, and similar operating
 matters.  Many factors may cause actual results to differ from forward-looking
 statements, including inaccurate assumptions and a broad variety of risks and
 uncertainties, some of which are known and others of which are not. Known
 risks and uncertainties include those identified from time to time in the
 reports filed by Generex with the Securities and Exchange Commission, which
 should be considered together with any forward-looking statement. No forward-
 looking statement is a guarantee of future results or events, and one should
 avoid placing undue reliance on such statements.  Generex claims the
 protection of the safe harbor for forward-looking statements that is contained
 in the Private Securities Litigation Reform Act.
 
 

SOURCE Generex Biotechnology Corporation
    TORONTO, Oct. 4 /PRNewswire-FirstCall/ -- Generex Biotechnology
 Corporation (Nasdaq:   GNBT), a leader in the area of buccal drug delivery,
 today announced that Dr. Jaime Guevara-Aguirre, of the Institute of
 Endocrinology IEMYR in Quito, Ecuador and one of the principal investigators
 in the Company's on-going clinical trials of Oral-lyn(TM), its proprietary
 oral insulin spray product, made a presentation of Oral-lyn(TM) clinical
 trials results at the 7th Hong Kong Diabetes and Cardiovascular Risk Factors -
 East Meets West Symposium on October 2, 2005.  Dr. Guevara-Aguirre made an
 oral presentation of an abstract entitled "Addition of Oral-lyn(TM) at
 Mealtimes in Subjects with Type-2 Diabetes Maintained on Glargine + Metformin
 - A Comparison with Placebo".  The abstract was coauthored by Professor Itamar
 Raz of Hadassah Hospital, Jerusalem, Israel (another Oral-lyn(TM) principal
 investigator) together with M. Kidron (also of Hadassah Hospital) and M.
 Dubinsky and J. Wainstein of Wolfson Hospital, Holon, Israel.
     In addition, Dr. Gerald Bernstein, the Company's Vice-President for
 Medical Affairs, will be making the following poster presentations at the Drug
 Discovery to Drug Development Global Partnering and New Science symposium in
 Mumbai, India from October 5 - 7, 2005:
 
     -- "A Series of Open-label Studies Comparing Various Formulations of
         Orally Administered Insulin (Oral-lyn(TM)) in Patients with Type-1
         Diabetes Mellitus (DM)", a study  coauthored by Dr. Jaime Guevara-
         Aguirre, Marco Guevara and Jeannette Saavedra of the Institute of
         Endocrinology IEMYR in Quito, Ecuador;
 
     -- "A 12-Day Comparison of Preprandial Humulin(R) vs. Oral-lyn(TM) in 10
         Type 1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy",
         a study coauthored by Dr. Jaime Guevara-Aguirre, Marco Guevara and
         Jeannette Saavedra of the Institute of Endocrinology IEMYR in Quito,
         Ecuador; and
 
     -- "Addition of Oral-lyn(TM) at Mealtimes in Subjects with Type 2 Diabetes
         Maintained on Glargine + Metformin - A Comparison with Placebo," a
         study coauthored by Professor Itamar Raz of Hadassah Hospital,
         Jerusalem, Israel together with M. Kidron (also of Hadassah Hospital)
         and M. Dubinsky and J. Wainstein of Wolfson Hospital, Holon, Israel.
 
     "The continuing acceptance at these significant scientific symposia of
 Oral-lyn(TM) studies is indicative of the increasing recognition in the global
 scientific community of our product's potential for providing a vast
 improvement in the quality of life of patients with diabetes," said Anna
 Gluskin, the Company's President & Chief Executive Officer.  "In addition, we
 welcome the increased exposure of Oral-lyn(TM) in the scientific communities
 in China and India, two potentially enormous markets for the product."
 
     About Generex
     Generex is engaged in the research and development of drug delivery
 systems and technologies.  Generex has developed a proprietary platform
 technology for the delivery of drugs into the human body through the oral
 cavity (with no deposit in the lungs).  The Company's proprietary liquid
 formulations allow drugs typically administered by injection to be absorbed
 into the body by the lining of the inner mouth using the Company's proprietary
 RapidMist(TM) device.  The Company's flagship product, oral insulin
 (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the
 treatment of patients with Type-1 and Type-2 diabetes, is in various stages of
 clinical trials around the world.
 
     For more information, visit the Generex Web site at
 http://www.generex.com.
 
     Safe Harbor Statement: This release and oral statements made from time to
 time by Generex representatives concerning the same subject matter may contain
 "forward-looking statements" within the meaning of the Private Securities
 Litigation Reform Act of 1995.  These statements can be identified by
 introductory words such as "expects," "plans," "intends," "believes," "will,"
 "estimates," "forecasts," "projects" or words of similar meaning, and by the
 fact that they do not relate strictly to historical or current facts.
 Forward-looking statements frequently are used in discussing potential product
 applications, potential collaborations, product development activities,
 clinical studies, regulatory submissions and approvals, and similar operating
 matters.  Many factors may cause actual results to differ from forward-looking
 statements, including inaccurate assumptions and a broad variety of risks and
 uncertainties, some of which are known and others of which are not. Known
 risks and uncertainties include those identified from time to time in the
 reports filed by Generex with the Securities and Exchange Commission, which
 should be considered together with any forward-looking statement. No forward-
 looking statement is a guarantee of future results or events, and one should
 avoid placing undue reliance on such statements.  Generex claims the
 protection of the safe harbor for forward-looking statements that is contained
 in the Private Securities Litigation Reform Act.
 
 SOURCE  Generex Biotechnology Corporation